Suppr超能文献

长期成人体重管理计划的临床效果和成本效益:系统评价。

The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review.

机构信息

Southampton Health Technology Assessments Centre, UK.

出版信息

Health Technol Assess. 2011 Jan;15(2):1-182. doi: 10.3310/hta15020.

Abstract

OBJECTIVE

To assess the long-term clinical effectiveness and cost-effectiveness of multicomponent weight management schemes for adults in terms of weight loss and maintenance of weight loss.

DATA SOURCES

Bibliographic databases were searched from inception to December 2009, including the Cochrane Library, MEDLINE (Ovid), EMBASE (Ovid), and MEDLINE In-Process & Other Non-Indexed Citations. Bibliographies of related papers were screened, key conferences and symposia were searched and experts were contacted to identify additional published and unpublished references.

REVIEW METHODS

For the clinical effectiveness review, two reviewers independently screened titles and abstracts for eligibility. Inclusion criteria were applied to the full text of retrieved papers by one reviewer and checked by a second reviewer using a pre-piloted inclusion flow chart. The studies were long-term randomised controlled trials (RCTs) of adult participants who were classified by body mass index as overweight or obese. Interventions were multicomponent weight management programmes (including diet, physical activity and behaviour change strategies) that assessed weight measures. Programmes that involved the use of over-the-counter medicines licensed in the UK were also eligible. For the cost-effectiveness review two reviewers independently screened studies for inclusion. Cost-effectiveness, cost-utility, cost-benefit or cost-consequence analyses were eligible. Data were extracted using a standardised and pre-piloted data extraction form. The quality of included studies was assessed using standard criteria. Studies were synthesised through a narrative review with full tabulation of results.

RESULTS

A total of 3358 references were identified, of which 12 were included in the clinical effectiveness review. Five RCTs compared multicomponent interventions with non-active comparator groups. In general, weight loss appeared to be greater in the intervention groups than in the comparator groups. Two RCTs compared multicomponent interventions that focused on the diet component. In these studies there were no statistically significant differences in weight loss between interventions. Four RCTs compared multicomponent interventions that focused on the physical activity component. There was little consistency in the pattern of results seen, in part owing to the differences in the interventions. In one RCT the intervention focused on the goal-setting interval and it appeared that weight loss was greatest in those given daily goals compared with weekly goals. Overall, where measured, it appeared that most groups began to regain weight at further follow-up. Of the 419 studies identified in the cost-effectiveness searches, none met the full inclusion criteria. Two economic evaluations are described in our review; however, caution is required in their interpretation, as they did not meet all inclusion criteria. Lifetime chronic disease models were used in these studies and the models included the costs and benefits of avoiding chronic illness. Both studies found the interventions to be cost-effective, with estimates varying between -£473 and £7200 (US$12,640) per quality-adjusted life-year gained; methodological omissions from these studies were apparent and caution is therefore required in the interpretation of these results.

CONCLUSIONS

Long-term multicomponent weight management interventions were generally shown to promote weight loss in overweight or obese adults. Weight changes were small however and weight regain was common. There were few similarities between the included studies; consequently an overall interpretation of the results was difficult to make. There is some evidence that weight management interventions are likely to be cost-effective, although caution is required as there were some limitations in the two cost-evaluation studies described.

FUNDING

The National Institute for Health Research Health Technology Assessment programme.

摘要

目的

评估多成分体重管理方案对成年人的长期临床效果和成本效益,包括减肥和维持减肥效果。

数据来源

从建库至 2009 年 12 月,对包括 Cochrane 图书馆、MEDLINE(Ovid)、EMBASE(Ovid)和 MEDLINE 处理中及其他未索引引文在内的文献数据库进行了检索。筛选了相关论文的参考文献,检索了主要会议和专题讨论会,并联系了专家以确定其他已发表和未发表的参考文献。

研究方法

对于临床效果评价,两名评审员独立筛选标题和摘要以确定是否符合入选标准。一名评审员应用纳入标准对检索到的论文全文进行评估,另一名评审员使用预先设定的纳入流程图进行核对。这些研究是对超重或肥胖成年人参与者进行的长期随机对照试验(RCT)。干预措施是多成分体重管理方案(包括饮食、身体活动和行为改变策略),评估体重测量结果。符合条件的研究还包括使用英国许可的非处方药物的方案。对于成本效果评价,两名评审员独立筛选研究以确定是否纳入。成本效果、成本效用、成本效益或成本后果分析符合条件。使用标准化和预先设定的数据提取表提取数据。使用标准标准评估纳入研究的质量。通过叙述性综述对研究进行综合,同时详细列出结果。

结果

共确定了 3358 条参考文献,其中 12 条纳入临床效果评价。5 项 RCT 比较了多成分干预与非活性对照组。一般来说,干预组的体重减轻似乎比对照组更明显。2 项 RCT 比较了专注于饮食成分的多成分干预。在这些研究中,干预之间的体重减轻没有统计学上的显著差异。4 项 RCT 比较了专注于身体活动成分的多成分干预。结果模式的一致性很小,部分原因是干预措施的差异。在一项 RCT 中,干预侧重于目标设定间隔,似乎每天设定目标的参与者比每周设定目标的参与者体重减轻更多。总体而言,在进一步随访时,大多数组似乎都开始恢复体重。在成本效益搜索中确定的 419 项研究中,没有一项完全符合纳入标准。我们的综述中描述了两项经济评估;但是,需要谨慎解释,因为它们没有完全符合纳入标准。这些研究使用了终生慢性疾病模型,模型包括避免慢性病的成本和效益。两项研究都发现干预措施具有成本效益,估计每获得一个质量调整生命年的成本在-473 英镑至 7200 英镑(12640 美元)之间;这些研究存在明显的方法学遗漏,因此需要谨慎解释这些结果。

结论

长期多成分体重管理干预措施通常可促进超重或肥胖成年人减肥。然而,体重变化很小,体重反弹很常见。纳入的研究之间几乎没有相似之处;因此,很难对结果进行总体解释。有一些证据表明体重管理干预措施可能具有成本效益,但需要谨慎,因为所描述的两项成本评估研究存在一些局限性。

资助

英国国家卫生研究院卫生技术评估计划。

相似文献

5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
10
Weight loss interventions for chronic asthma.
Cochrane Database Syst Rev. 2012 Jul 11;2012(7):CD009339. doi: 10.1002/14651858.CD009339.pub2.

引用本文的文献

4
Eating in the Absence of Hunger Is a Stable Predictor of Adiposity Gains in Middle Childhood.
J Nutr. 2024 Dec;154(12):3726-3739. doi: 10.1016/j.tjnut.2024.10.008. Epub 2024 Oct 10.
5
GLP-1-based therapies for the treatment of resistant hypertension in individuals with overweight or obesity: a review.
EClinicalMedicine. 2024 Aug 15;75:102789. doi: 10.1016/j.eclinm.2024.102789. eCollection 2024 Sep.
7
E4bp4-Cyp3a11 axis in high-fat diet-induced obese mice with weight fluctuation.
Nutr Metab (Lond). 2024 May 27;21(1):30. doi: 10.1186/s12986-024-00803-1.
8
The alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 reduces food intake in male rats.
Pharmacol Biochem Behav. 2024 Apr;237:173723. doi: 10.1016/j.pbb.2024.173723. Epub 2024 Feb 7.
10
New insights in the mechanisms of weight-loss maintenance: Summary from a Pennington symposium.
Obesity (Silver Spring). 2023 Dec;31(12):2895-2908. doi: 10.1002/oby.23905. Epub 2023 Oct 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验